Organic Active Ingredients TRIZ Cases

Combining bispecific antibodies with lenalidomide or ibrutinib improves survival in relapsed diffuse large B-cell lymphoma.

Incorporates sulfur-containing 2-mercaptobenzimidazole into the adhesive layer to inhibit butorphanol oxidant generation and prevent crystal precipitation.

A 4-amino-1,8-naphthalimide compound disrupts calcified plaque crystalline structures to restore vascular compliance.

A polyhydroxyalkanoate powder composition with silicate additives enables effective plaque removal during dental air polishing procedures.

Antibodies bind c-Met to modulate activity, resolving the trade-off between inhibiting cancer metastasis and stimulating tissue regeneration.

A 16,17-annellated steroid compound selectively activates estrogen receptors to treat endometriosis.

Enzymatically-cleavable fluorescent esters facilitate high-efficiency cellular uptake of phosphoantigen prodrugs.

5,7-disubstituted thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives inhibit CX3CR1 while reducing off-target CXCR2 binding.

Alpha B-crystallin acts as a molecular chaperone to protect CNS cells, addressing the limited efficacy of current immunomodulatory therapies.

Targeted USP7 inhibition stabilizes p53 to activate apoptosis, avoiding toxicity from broad proteasome blockade.

JNJ-37822681 activates Kv7.2/7.3 potassium channels to treat pharmacoresistant epilepsy without retigabine side effects.

Deuterated pyrimidin-5-ol derivatives improve metabolic stability via parameter changes to treat mitochondrial diseases with diminished ATP.

P-glycoprotein inhibitors reverse multidrug resistance by blocking chemotherapeutic agent export from cancer cells.

Peptide linkers in doxorubicin conjugates reduce normal cell toxicity while maintaining anti-tumor efficacy through enzyme-specific activation.

Monocytes loaded with alpha-galactosylceramide and tumor antigens activate cytotoxic T cells to target malignant tumors.

Cyclodextrin acts as an intermediary substance to enhance dissolution rates and tablet strength without increasing formulation complexity.

Plk1 and ubiquitin siRNA combination induces apoptosis, resolving time-consuming manual assessment bottlenecks in high-throughput screening.

Locked nucleic acid oligonucleotides inhibit telomeric non-coding RNAs, sparing normal cells from the adverse side effects of non-sequence-specific DNA damage.

RNA oligonucleotides bind YB-1 protein motifs to inhibit tumor cell proliferation, addressing glioblastoma drug resistance.

Mycophenolic acid depletes guanosine while melanin generates reactive oxygen species to inhibit viral replication.

Novel pyrrolidine beta-3 adrenergic receptor agonists relax the detrusor muscle to treat urinary disorders.

Modified nucleosides inhibit HCV replication via polymerase interference while reducing toxicity and resistance compared to existing therapies.

Targeted nanoparticles activate ablative agents in specific myocytes to spare bystander cells, reducing perforation risks and recurrence.

A nanoparticle uses transferrin ligands to cross the blood-brain barrier via receptor-mediated transcytosis.

Segmenting opioid effects via composite phenylpiperazine structures delivers strong pain relief without addiction or respiratory depression.

A GPC3-specific DNA aptamer targets hepatocellular carcinoma cells, reducing side effects from non-specific protein binding.

Selective HCK inhibitors overcome BTK resistance by targeting downstream kinases to induce apoptosis.

Immature hemp leaf extract inhibits platelet aggregation and coagulation factors to prevent thrombus formation.

Combining TPTE and CXCR4 expression levels enables accurate distant metastasis detection in biological samples.

High-affinity CTLA4 mutants block costimulatory signals to prevent graft rejection without calcineurin inhibitor nephrotoxicity.

Terminal 5' modifications protect oligomeric compounds from nuclease degradation while preserving RNA hybridization and targeting specificity.

Assessing gestational diabetes susceptibility in Mexican populations by identifying specific TCF7L2 and KCNQ1 haplotypes to resolve prediction reliability gaps.

Pyrazolopyrazine compounds inhibit PTPN11 activity, resolving limited therapeutic options for cancers and Noonan Syndrome.

Green mango extract replaces synthetic chemicals to inhibit melanin production, preventing ultraviolet damage while suppressing collagen glycation.

Extragranular disintegrant addition preserves activity lost during wet granulation, improving dissolution profiles for multiple sclerosis treatments.

Novel 8-alkoxy-2-aminotetralin derivatives directly activate soluble guanylate cyclase to promote vascular relaxation.

Crystalline sodium salt of a TAFIa inhibitor resists water uptake through controlled phase transitions, resolving hygroscopicity and chemical instability.

Cyclodextrin inclusion complexes prevent segregation and degradation of low-dose fingolimod, maintaining content uniformity.

Acyclic linker cap analogs replace ribose with linear structures to enhance eIF-4E binding and co-transcriptional capping efficiency.

Solid phosphonate salts dissolve calcium ions to remove root canal smear layers without degrading oxidizing agents.

Non-imidazole alkylamine ligands resolve blood-brain barrier penetration and toxicity trade-offs while maintaining high H3-receptor antagonism potency.

A gene signature framework evaluates multiple biomarkers to predict cancer cell sensitivity to MDM2 inhibitors.